In accordance
with 5 CFR 1320, the information collection is approved. The agency
is reminded that the type of burden (recordkeeping, reporting,
third-party disclosure) should be properly entered in the ROCIS
system.
Inventory as of this Action
Requested
Previously Approved
04/30/2015
36 Months From Approved
04/30/2012
1,248,727
0
1,174,427
848,625
0
798,132
0
0
0
The CGMP regulations help ensure that
drug products meet the statutory requirements for safety and have
their purported or represented identity, strength, quality, and
purity characteristics. The information collection requirements in
the CGMP regulations are necessary to establish accountability in
the manufacturing and processing of drug products, provide for
meaningful FDA inspections, and enable manufacturers to improve the
quality of drug products over time. The CGBP recordkeeping
requirements also serve as crucial information if it is necessary
to recall a drug product.
Johnny Vilela 301 796-3792
juanmanuel.vilela@fda.hhs.gov
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.